Factors Affecting the Receptiveness of Chinese Internists and Surgeons Toward Artificial Intelligence-Driven Drug Prescription: Protocol for a Systematic Survey Study.

Background: Recently, we developed and tested an autonomous artificial intelligence (AI) agent for prescribing a drug to prevent severe acute graft-versus-host disease in patients receiving human leukocyte antigen haplotype-mismatched hematopoietic cell transplants in a prospective clinical trial. Our experience in this proof-of-concept study suggests that physicians and patients can be receptive to autonomous AI prescription. However, the generalizability of our conclusion requires testing in additional clinical settings.

Predicting survival of persons with newly-diagnosed multiple myeloma.

Background: Predicting survival in newly diagnosed multiple myeloma (NDMM) patients accurately remains challenging. Although mSMART3.0 is widely used it has not been rigorously tested for prediction accuracy.

The bone marrow immune ecosystem shapes daratumumab acquired resistance in plasma cell myeloma.

Daratumumab, an anti-CD38 monoclonal antibody, is an effective therapy for plasma cell myeloma (PCM). However, many initial responders relapse. We compared paired samples from subjects pre-therapy and then acquired resistance to daratumumab.

Beyond CAR-T: The Rise of CAR-NK/T Cells for Haematological Cancer.

Background: Chimeric antigen receptor (CAR)-natural killer (NK)/T-cells offer a new approach in immune therapy of haematological cancers. NK/T-cells bridge innate and adaptive immunity with strong anti-cancer effects. Unlike allogeneic CAR-T-cells, CAR-NK/T-cells do not require TCR genetic deletion to prevent major MHC recognition, have a lower risk of graft-versus-host disease, and can be used universally.

CAR-NK cells for haematological cancers.

Chimeric antigen receptor-natural-killer (CAR-NK)-cells are a promising cancer cell therapy. Several features of CAR-NK-cells are suggesting an advantage over CAR-T-cells such as less complex manufacturing, "off-the-shelf" use and lower risks of cytokine release (CRS) and immune effector cell-associated neurotoxicity syndromes (ICANS). CAR-NK-cells derived from several sources are associated with promising pre-clinical and clinical results in haematological cancers.

Comparative analysis of patients' characteristics, treatment, and survival outcomes in CLL from China and the United States.

Background: Chronic lymphocytic leukemia (CLL) is considerably more common in Americans compared with Asians. The basis for these differences and implications for therapy outcomes are controversial and mostly unknown.

Methods: We compared baseline co-variates, therapies, and outcomes from 2 databases, Flatiron Health database in the United States (N = 15 786) and Tianjin CAMS database from China (N = 2996).

Primary myelofibrosis with increased haemoglobin concentration at presentation.

One hundred of 963 consecutive registrants with primary myelofibrosis (PMF) in the Pavia-CSM database had haemoglobin concentration at diagnosis ≥160 g/L in females or ≥ 165 g/L in males. These subjects were more often female and younger; had higher white blood cell (WBC) and platelet concentrations; and higher frequency of JAK2 and JAK2 variant allele frequency (VAF) compared with those without increased haemoglobin at diagnosis. They had less active disease defined as smaller spleen, lower plasma lactate dehydrogenase, lower blood CD34-positive cell concentration and less bone marrow fibrosis.

Prognostic impact of dynamic changes of type I melanoma antigen gene proteins CT7 () transcripts in multiple myeloma.

Type I melanoma antigen gene proteins CT7 (), a cancer-testis (CT) gene, correlated with clinical parameters at diagnosis of multiple myeloma (MM). We first analyzed single-cell ribonucleic acid sequencing data from public databases to evaluate the expression of in MM patients and showed that is highly and specifically expressed in the MM cells. We then interrogated data from 216 consecutive cases with transcripts by quantitative real-time polymerase chain reaction longitudinally monitored in our center.

Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia.

Optimizing olverembatinib dose in people with chronic phase chronic myeloid leukemia (CML) is important to increase safety without compromising efficacy. We designed a multi-center retrospective study comparing safety and efficacy of olverembatinib between the recommended dose of 40 mg every other day (QOD; N = 216) and a reduced dose of 30 mg QOD (N = 66) in subjects failing other tyrosine kinase-inhibitors (TKIs). The cohorts were similar in baseline co-variates and adjusted for by propensity score matching (PSM).

Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia.

Vamotinib (PF-114) is a 3rd -generation, ATP-competitive oral tyrosine kinase inhibitor (TKI) active against wild-type and mutated BCR::ABL1 isoforms including BCR::ABL1. We present final results of a phase-1 vamotinib dose-escalation study to identify maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) followed by expansion cohorts. 51 subjects with chronic myeloid leukaemia (CML) failing ≥ 1 2nd generation TKI or with BCR::ABL1 were enrolled.

A Visual Nomogram Survival Prediction Model in Acquired Immune Deficiency Syndrome (AIDS)-Related Diffuse Large B-Cell Lymphoma.

Estimating the prognosis of people with newly diagnosed AIDS-related diffuse large B-cell lymphoma (AR-DLBCL) is challenging. We did a prospective, multicenter cohort study using data from 306 consecutive subjects, including training cohort (N = 215) and external validation cohorts (N = 91), to develop and validate a visual nomogram, termed the ARDPI model. Seven co-variates were independently correlated with survival, including age, LMR, CD5, blood EBV-DNA copy number, CD4/CD8, CNS involvement, and anti-HIV therapy (ART), were used to develop the ARDPI model.

Cytokine therapy of acute radiation syndrome.

Radiological accidents/incidents are common with nearly 400 reported since 1944 exposing about 3000 people to substantial doses of ionizing radiations with 127 deaths. Damage to hematopoietic stem and progenitor cells with resulting bone marrow failure is a common consequence of exposure to whole body acute high-dose and -dose-rate ionizing radiations and is termed hematopoietic-acute radiation syndrome, or H-ARS. Therapy of H-ARS includes transfusions, anti-bacterial and -viral drugs, molecularly-cloned hematopoietic growth factors and hematopoietic cell transplants.

A novel prognostic model utilizing TMTV and SUVmax from F-FDG PET/CT for predicting overall survival in patients with extranodal NK/T- cell lymphoma.

Background: Survival prediction accuracy of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) in extra-nodal natural killer/T-cell lymphoma (ENKTL) is controversial. This study aimed to evaluate the prognostic value of F-FDG PET/CT parameters including maximum standardized uptake value (SUVmax), total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG), and to develop a new prognostic model for ENKTL.

Methods: We analyzed 390 ENKTL patients with comprehensive clinical and survival data.

Survival outcomes between haploidentical stem cell transplantation and chemotherapy for blastic plasmacytoid dendritic cell neoplasm.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy with poor clinical outcomes. Stem cell transplantation helps to achieve long-term survival in adults. However, the benefit of haploidentical stem cell transplantation (HID-SCT) versus chemotherapy is unclear with BPDCN.